Spin-off - Medtronic plc

Form Type: 8-K

Filing Date: 2025-05-21

Corporate Action: Spin-off

Type: New

Accession Number: 000161310325000078

Filing Summary: On May 21, 2025, Medtronic plc reported its full year and fourth quarter fiscal year 2025 financial results and announced the intent to spin off its Diabetes business into a new standalone public company. Sean Salmon, the EVP and President of the Cardiovascular Portfolio, will be departing from his position, with Skip Kiil assuming this role effective the same day. Salmon will remain an employee until September 2, 2025, receiving severance benefits in line with company practices. The press releases detailing the financial results and the separation of the Diabetes business were attached as Exhibits 99.1 and 99.2 respectively.